[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"upper-aero-digestive-tract-uadt-neoplasm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:upper-aero-digestive-tract-uadt-neoplasm":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100639254","ai-assisted-endoscopy-for-upper-aerodigestive-tract-lesions-100639254",false,"NCT07596355","AI-Assisted Endoscopy for Upper Aerodigestive Tract Lesions","Head&Neck Application of Novel Computer-assisted Endoscopy","H&NANCE","Inclusion Criteria:\n\n* Age \\> 18 years\n* Injury originating from the upper aero-digestive tract\n* Recording of the video-endoscopic examination\n* Patient known to undergo a biopsy of the lesion or clinical follow-up for lesion with known biopsy (e.g. laryngeal papillomatosis) or suffering from Reinke's edema (in this pathology, in fact, biopsy is not necessary since the diagnosis is clinical)\n* Or patients undergoing transoral lesion excision\n\nExclusion Criteria:\n\n* Submucosal lesion\n* Patients with previous operations on the upper aero-digestive tract\n* Patients with previous radiotherapy of the head and neck district\n* Poor compliance on endoscopic examination\n* Unavailability of CADe\u002FCADx or CASe data logging note","ALL","18 Years",{"count":20,"type":21},283,"ESTIMATED","OBSERVATIONAL","This is a prospective observational clinical study designed to evaluate the performance of artificial intelligence (AI) algorithms applied to upper aerodigestive tract (UADT) video-endoscopy. The study assesses three main tasks: lesion detection (localization), classification (benign vs malignant), and segmentation of tumor margins.\n\nAI algorithms will be applied to endoscopic video data acquired during routine clinical practice without influencing clinical decision-making. The system will process images in real time and store data for subsequent analysis. AI outputs will be compared with physician assessment and reference standard histopathology to evaluate diagnostic performance.",[25,26,27,28,29,30,31,32,33],"Upper Aerodigestive Tract Neoplasms","Upper AerodigestiveTract Cancer","Upper Aero-digestive Tract (UADT) Neoplasm","Squamous Cell Carcinoma","Leukoplakia","Head and Neck Cancer (H&N)","Vocal Cord Disease","Vocal Fold Polyp","Vocal Fold Nodules","NOT_YET_RECRUITING","2026-05-12",{"date":37,"type":38},"2026-05-19","ACTUAL",{"date":40,"type":21},"2026-05",{"date":42,"type":21},"2028-02",{"name":44,"class":45},"Istituto Italiano di Tecnologia","OTHER",3,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100552898","prognostic-value-of-measuring-ctdna-in-a-cohort-of-patients-with-stage-iii-and-iv-upper-aero-digestive-tract-uadt-cancer--treated-with-curative-radiotherapy-with-or-without-concomitant-treatment-100552898","NCT06479070","Prognostic Value of Measuring CtDNA in a Cohort of Patients With Stage III and IV Upper Aero-digestive Tract (UADT) Cancer , Treated With Curative RADiOtherapy With or Without Concomitant Treatment.","Prognostic Value of Measuring Circulating Tumor DNA in a Cohort of Patients With Stage III and IV UADT Cancer, Treated With Curative RADiOtherapy With or Without Concomitant Treatment.","CIRADOR","Inclusion Criteria\n\n* OMS 0 to 2;\n* Patient suffering from UADT squamous cell carcinoma, newly diagnosed and histologically proven, regardless of the p16 protein status, naïve to any treatment for this cancer;\n* Non-metastatic cancer of stages III (N1), IVa (N1 minimum) or IVb;\n* Cancer localized in the oral cavity, larynx, oropharynx, hypopharynx and maxillary sinus;\n* Patient for whom treatment with curative radiotherapy associated or not with concomitant treatment (Cisplatin or Cetuximab) has been validated in a multidisciplinary consultation meeting (RCP);\n* Patient capable and willing to follow all study procedures in accordance with the protocol;\n* Patient having understood, signed and dated the consent form communicated on the day of inclusion;\n* Patient affiliated to the social security system.\n\nExclusion Criteria:\n\n* Minor patient;\n* Cancer located in the cavum, ethmoidal sinus, salivary glands and skin (cutaneous squamous cell carcinoma);\n* Patient already treated for UADT tumor;\n* Patient treated with immunotherapy;\n* Patient who has already had cancer within 5 years (cancer other than in the UADT sphere);\n* OMS \\> 2;\n* Contraindication to radiotherapy treatment associated or not with concomitant treatment;\n* Patient already included in another therapeutic trial;\n* Metastatic disease (stage IVc);\n* Pregnant woman, who may be pregnant, or currently breastfeeding;\n* Persons deprived of liberty or under guardianship (including curatorship).",{"count":56,"type":21},188,"INTERVENTIONAL",[59],"NA","Squamous cell carcinomas of the upper aero-digestive tract (SCC-UADT) represent the seventh cause of cancer and affect approximately 600,000 patients per year worldwide. The majority of UADT cancers are diagnosed at an advanced stage (70.3% at stage III and IV) and less than 60% of these patients are free of the disease at 3 years, despite aggressive multimodal local treatment by surgery and \u002For radiochemotherapy. The average progression-free survival (PFS) at 2 years varies between 45 and 60% depending on the studies. Tumor recurrence is most often incurable. To our knowledge, no study has demonstrated the benefit of early evaluation of the rate of decrease in ctDNA at 1 month after the end of radiotherapy alone or associated with concomitant treatment, as a predictive factor of PFS in UADT squamous cell carcinomas regardless of their HPV status. The main objective of this study is to evaluate the value of measuring the quantity of circulating tumor DNA (ctDNA) at 1 month post-treatment as a predictive factor for PFS at 24 months.",[62,27],"SCC - Squamous Cell Carcinoma",[28,64,65,66,67],"upper aero-digestive trac tumor","Ct DNA","Radiotherapy","Head and neck cancer","RECRUITING","2025-12-18",{"date":71,"type":38},"2025-12-24",{"date":73,"type":38},"2024-09-30",{"date":75,"type":21},"2029-09-30",{"name":77,"class":45},"Institut de Cancérologie de Lorraine",7]